2022 NIAID Omnibus Broad Agency Announcement

Award Notice Posted

Solicitation number
HHS-NIH-NIAID-BAA2022-1
Agency
Awarded
to Baruch S. Blumberg Institute
Set-aside
No set-aside

Opportunity facts

Contract number
75N93023C00003 Federal contract award

Notice details come from SAM.gov. Updated .

About this opportunity

The National Institute of Allergy and Infectious Diseases awarded a cost-reimbursement contract valued at $3,348,261 to BARUCH S BLUMBERG INSTITUTE on November 15, 2022 under the 2022 NIAID Omnibus Broad Agency Announcement. This full and open competition contract was selected as a cost-reimbursement vehicle to support the development of an orally available small molecule antiviral drug to treat yellow fever virus infection over an unspecified period of performance, as costs could not be adequately defined at time of award.

Notice text

This cost-reimbursement contract award was made under full and open competition. This type of contract was selected because costs cannot be adequately defined at the time of contract award. This contract is to develop an orally available small molecule antiviral drug, with treatment of yellow fever virus infection as the primary indication.

Awarded contract 75N93023C00003 to BARUCH S BLUMBERG INSTITUTE for 32348261.00 on 2022-11-15.

Notice history

Notice Type Posted
2022 NIAID Omnibus Broad Agency Announcement Latest Award Notice
This notice Award Notice
2022 NIAID Omnibus Broad Agency Announcement Award Notice
2022 NIAID Omnibus Broad Agency Announcement Award Notice
2022 NIAID Omnibus Broad Agency Announcement Latest solicitation Solicitation
2022 NIAID Omnibus Broad Agency Announcement Original Pre-Solicitation

Similar open opportunities

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors